Genetic Polymorphism oriented PhaseI Study of Irinotecan and Doxifluridine for Unresectable or Recurrent Colorectal Cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs Doxifluridine (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 26 Jun 2009 Status changed from not stated to active, no longer recruiting.
- 26 Jun 2009 New trial record